- Research works
- 9 ▼ 100% vs 2013–17
- Citations
- 84 8.9 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 67% world 28%
Not ranked overall: CIS Pharma (Switzerland) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which research topics does CIS Pharma (Switzerland) publish most on?
By volume in 2022–2025: Neuroblastoma Research and Treatments, Lung Cancer Research Studies and Cancer therapeutics and mechanisms.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Neuroblastoma Research and Treatments Neurology 0 works
- 2 Lung Cancer Research Studies Oncology 0 works
- 3 Cancer therapeutics and mechanisms Molecular Biology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has CIS Pharma (Switzerland)'s research output changed?
Output in 2018–2022 was 100% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Bubendorf
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.